Cytomegalovirus retinitis during AIDS: Current issues and future directions

R. D. Dix, Carolyn Cray, S. Cousins

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Cytomegalovirus (CMV) retinitis is the leading cause of blindness in patients with acquired immune deficiency syndrome (AIDS). Before improved therapeutic approaches can be developed to manage this devastating sight- threatening disease, specific questions pertinent to the pathophysiology of CMV retinitis must be addressed. These questions relate to the origin of virus responsible for retinitis, spread of virus within the retina, the immunopathogenesis of retinal destruction, and the fate of virus during traditional antiviral therapy. In this review, we examine for each question the clinical rationale, the experimental data, and the clinical implications associated with these data. In particular, two experimental systems are emphasized. One is an in vitro system to study the susceptibility of human retinal pigment epithelium to CMV infection. The other involves clinically- relevant murine models of CMV retinitis, especially one of retrovirus- induced immunodeficiency (MAIDS). We suggest that immune-based therapy alone or in combination with traditional chemotherapy offers improved prospects for maintaining subclinical CMV infection in the immunosuppressed individual, thereby preventing CMV retinitis.

Original languageEnglish
Pages (from-to)112-118
Number of pages7
JournalRegional immunology
Volume6
Issue number1-2
StatePublished - Dec 1 1994

Fingerprint

Cytomegalovirus Retinitis
Acquired Immunodeficiency Syndrome
Cytomegalovirus Infections
Viruses
Murine Acquired Immunodeficiency Syndrome
Muromegalovirus
Retinitis
Asymptomatic Infections
Retinal Pigment Epithelium
Retroviridae
Blindness
Antiviral Agents
Retina
Therapeutics
Drug Therapy
Direction compound

ASJC Scopus subject areas

  • Immunology

Cite this

Cytomegalovirus retinitis during AIDS : Current issues and future directions. / Dix, R. D.; Cray, Carolyn; Cousins, S.

In: Regional immunology, Vol. 6, No. 1-2, 01.12.1994, p. 112-118.

Research output: Contribution to journalArticle

@article{173d8c4a1e78499aa3a1ca855a05fbea,
title = "Cytomegalovirus retinitis during AIDS: Current issues and future directions",
abstract = "Cytomegalovirus (CMV) retinitis is the leading cause of blindness in patients with acquired immune deficiency syndrome (AIDS). Before improved therapeutic approaches can be developed to manage this devastating sight- threatening disease, specific questions pertinent to the pathophysiology of CMV retinitis must be addressed. These questions relate to the origin of virus responsible for retinitis, spread of virus within the retina, the immunopathogenesis of retinal destruction, and the fate of virus during traditional antiviral therapy. In this review, we examine for each question the clinical rationale, the experimental data, and the clinical implications associated with these data. In particular, two experimental systems are emphasized. One is an in vitro system to study the susceptibility of human retinal pigment epithelium to CMV infection. The other involves clinically- relevant murine models of CMV retinitis, especially one of retrovirus- induced immunodeficiency (MAIDS). We suggest that immune-based therapy alone or in combination with traditional chemotherapy offers improved prospects for maintaining subclinical CMV infection in the immunosuppressed individual, thereby preventing CMV retinitis.",
author = "Dix, {R. D.} and Carolyn Cray and S. Cousins",
year = "1994",
month = "12",
day = "1",
language = "English",
volume = "6",
pages = "112--118",
journal = "Regional immunology",
issn = "0896-0623",
number = "1-2",

}

TY - JOUR

T1 - Cytomegalovirus retinitis during AIDS

T2 - Current issues and future directions

AU - Dix, R. D.

AU - Cray, Carolyn

AU - Cousins, S.

PY - 1994/12/1

Y1 - 1994/12/1

N2 - Cytomegalovirus (CMV) retinitis is the leading cause of blindness in patients with acquired immune deficiency syndrome (AIDS). Before improved therapeutic approaches can be developed to manage this devastating sight- threatening disease, specific questions pertinent to the pathophysiology of CMV retinitis must be addressed. These questions relate to the origin of virus responsible for retinitis, spread of virus within the retina, the immunopathogenesis of retinal destruction, and the fate of virus during traditional antiviral therapy. In this review, we examine for each question the clinical rationale, the experimental data, and the clinical implications associated with these data. In particular, two experimental systems are emphasized. One is an in vitro system to study the susceptibility of human retinal pigment epithelium to CMV infection. The other involves clinically- relevant murine models of CMV retinitis, especially one of retrovirus- induced immunodeficiency (MAIDS). We suggest that immune-based therapy alone or in combination with traditional chemotherapy offers improved prospects for maintaining subclinical CMV infection in the immunosuppressed individual, thereby preventing CMV retinitis.

AB - Cytomegalovirus (CMV) retinitis is the leading cause of blindness in patients with acquired immune deficiency syndrome (AIDS). Before improved therapeutic approaches can be developed to manage this devastating sight- threatening disease, specific questions pertinent to the pathophysiology of CMV retinitis must be addressed. These questions relate to the origin of virus responsible for retinitis, spread of virus within the retina, the immunopathogenesis of retinal destruction, and the fate of virus during traditional antiviral therapy. In this review, we examine for each question the clinical rationale, the experimental data, and the clinical implications associated with these data. In particular, two experimental systems are emphasized. One is an in vitro system to study the susceptibility of human retinal pigment epithelium to CMV infection. The other involves clinically- relevant murine models of CMV retinitis, especially one of retrovirus- induced immunodeficiency (MAIDS). We suggest that immune-based therapy alone or in combination with traditional chemotherapy offers improved prospects for maintaining subclinical CMV infection in the immunosuppressed individual, thereby preventing CMV retinitis.

UR - http://www.scopus.com/inward/record.url?scp=0028652372&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028652372&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0028652372

VL - 6

SP - 112

EP - 118

JO - Regional immunology

JF - Regional immunology

SN - 0896-0623

IS - 1-2

ER -